Increased Plasma Levels of Triglyceride-Enriched Lipoproteins Associate with Systemic Inflammation, Lipopolysaccharides, and Gut Dysbiosis in Common Variable Immunodeficiency.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
08 2023
Historique:
received: 22 12 2022
accepted: 15 03 2023
medline: 21 7 2023
pubmed: 31 3 2023
entrez: 30 3 2023
Statut: ppublish

Résumé

Triglycerides (TG) and their major transport lipoprotein in the circulation (VLDL) appear to be related to inflammation. Patients with common variable immunodeficiency (CVID) have inflammatory complications associated with gut microbial dysbiosis. We hypothesized that CVID patients have disturbed TG/VLDL profiles associated with these clinical characteristics. We measured plasma concentrations of TGs, inflammatory markers, and lipopolysaccharide (LPS) in 95 CVID patients and 28 healthy controls. Additionally, in 40 CVID patients, we explored plasma lipoprotein profiling, fatty acid, gut microbial dysbiosis, and diet. TG levels were increased in CVID patients as compared to healthy controls (1.36 ± 0.53 mmol/l versus 1.08 ± 0.56 [mean, SD], respectively, P = 0.008), particularly in the clinical subgroup "Complications," characterized by autoimmunity and organ-specific inflammation, compared to "Infection only" (1.41 mmol/l, 0.71[median, IQR] versus [1.02 mmol/l, 0.50], P = 0.021). Lipoprotein profile analyses showed increased levels of all sizes of VLDL particles in CVID patients compared to controls. TG levels correlated positively with CRP (rho = 0.256, P = 0.015), IL-6 (rho = 0.237, P = 0.021), IL-12 (rho = 0.265, P = 0.009), LPS (r = 0.654, P = 6.59 × 10 We found increased plasma levels of TGs and all sizes of VLDL particles, which were associated with systemic inflammation, LPS, and gut dysbiosis in CVID, but not diet or BMI.

Identifiants

pubmed: 36995502
doi: 10.1007/s10875-023-01475-x
pii: 10.1007/s10875-023-01475-x
pmc: PMC10353950
doi:

Substances chimiques

Lipopolysaccharides 0
Lipoproteins 0
Triglycerides 0
Fatty Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1229-1240

Informations de copyright

© 2023. The Author(s).

Références

Ann Nutr Metab. 2015;66(4):237-241
pubmed: 26183722
Crit Care Med. 2003 Jun;31(6):1647-53
pubmed: 12794399
Mucosal Immunol. 2016 Nov;9(6):1455-1465
pubmed: 26982597
Blood. 2008 Jul 15;112(2):277-86
pubmed: 18319398
Circ Res. 2015 Oct 9;117(9):817-24
pubmed: 26358192
Am J Epidemiol. 1999 Jul 1;150(1):75-87
pubmed: 10400557
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
J Exp Med. 1996 Nov 1;184(5):1601-8
pubmed: 8920850
Infect Immun. 2001 May;69(5):2821-8
pubmed: 11292694
J Clin Immunol. 2019 Jan;39(1):30-36
pubmed: 30465180
Diabetes Care. 2011 Feb;34(2):392-7
pubmed: 21270197
Int J Mol Sci. 2022 Apr 13;23(8):
pubmed: 35457118
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
J Clin Immunol. 2022 Jan;42(1):146-157
pubmed: 34669143
Innate Immun. 2008 Aug;14(4):247-53
pubmed: 18669610
Sci Rep. 2019 Jan 17;9(1):167
pubmed: 30655568
J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):425-33
pubmed: 23797689
Sci Rep. 2021 Nov 9;11(1):21936
pubmed: 34754007
J Allergy Clin Immunol. 2019 May;143(5):1969-1971.e11
pubmed: 30707969
Clin Infect Dis. 2008 May 15;46(10):1547-54
pubmed: 18419489
Blood. 2012 Feb 16;119(7):1650-7
pubmed: 22180439
Metabolites. 2021 Aug 10;11(8):
pubmed: 34436472
Nat Immunol. 2020 Jan;21(1):30-41
pubmed: 31819254
Front Endocrinol (Lausanne). 2022 Feb 03;13:839436
pubmed: 35185805
Lipids Health Dis. 2012 Jun 27;11:82
pubmed: 22738017
J Acad Nutr Diet. 2012 Jul;112(7):1029-41, 1041.e1-15
pubmed: 22889633
BMC Med Res Methodol. 2012 Sep 14;12:143
pubmed: 22978749
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Clin Chem. 2019 Feb;65(2):321-332
pubmed: 30518661
J Lipid Res. 2009 Feb;50(2):204-13
pubmed: 18812596
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Future Cardiol. 2006 May;2(3):315-23
pubmed: 19804089
Blood. 2010 Jul 8;116(1):7-15
pubmed: 20332369
Ann Intern Med. 1988 Apr;108(4):609-12
pubmed: 3348567
Clin Exp Immunol. 1999 Oct;118 Suppl 1:1-28
pubmed: 10540200
Front Immunol. 2020 Jun 19;11:1245
pubmed: 32636843
Sci Rep. 2019 Jul 1;9(1):9427
pubmed: 31263122
Br J Nutr. 2005 Apr;93(4):519-27
pubmed: 15946415
Molecules. 2020 May 09;25(9):
pubmed: 32397353
Front Mol Biosci. 2022 May 25;9:909151
pubmed: 35693558
Curr Med Chem. 2019;26(9):1701-1710
pubmed: 29848270
Front Immunol. 2020 Sep 16;11:574500
pubmed: 33042155
BMC Microbiol. 2010 Jul 30;10:206
pubmed: 20673359

Auteurs

Magnhild E Macpherson (ME)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Tonje Skarpengland (T)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Johannes R Hov (JR)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Section of Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway.

Trine Ranheim (T)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Beate Vestad (B)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Tuva B Dahl (TB)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Department of Acute Medicine, Oslo University Hospital, Oslo, Norway.

Mai S A Fraz (MSA)

Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Annika E Michelsen (AE)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Kirsten B Holven (KB)

Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway.
Norwegian National Advisory Unit On Familial Hypercholesterolemia, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Børre Fevang (B)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Centre for Rare Disorders, Oslo University Hospital, Oslo, Norway.

Rolf K Berge (RK)

Department of Clinical Science, University of Bergen, N-5020, Bergen, Norway.
Department of Heart Disease, Haukeland University Hospital, N-5021, Bergen, Norway.

Pål Aukrust (P)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Bente Halvorsen (B)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Silje F Jørgensen (SF)

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. s.f.jorgensen@medisin.uio.no.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. s.f.jorgensen@medisin.uio.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH